|Focus on ASCVD Risk Reduction: 4 Statin Benefit Groups|
|A New Perspective on LDL-C and/or Non–HDL-C Goals|
|Global Risk Assessment for Primary Prevention|
|Role of Biomarkers and Noninvasive Tests|
|Future Updates to the Blood Cholesterol Guideline|
∗For additional information, see http://www.mesa-nhlbi.org/CACReference.aspx.
AIM-HIGH indicates Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes; ACCORD, Action to Control Cardiovascular Risk in Diabetes; Apo B, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CQ, critical question; FDA, U.S. Food and Drug Administration; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); NHANES, National Health and Nutrition Examination Survey; and RCTs, randomized controlled trials.